This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Strong Demand Fuel United Natural's (UNFI) Q2 Earnings
by Zacks Equity Research
United Natural's (UNFI) Q2 results to gain from robust demand conditions and buyouts. However, rising fright costs and unfavorable consumer mix are concerns.
What Bargain Hunting? Bet on 5 Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
British American (BTI) 2018 Earnings: Pricing a Key Catalyst
by Zacks Equity Research
British American's (BTI) preliminary 2018 results to gain from robust pricing as well as growth in low-risk tobacco products.
Factors Setting the Tone for FEMSA (FMX) in Q4 Earnings
by Zacks Equity Research
FEMSA's (FMX) fourth-quarter 2018 results might be hurt by higher operating expenses. However, its strategic actions to boost growth remain encouraging.
Estee Lauder Hits 52-Week High: What's Behind the Rally?
by Zacks Equity Research
Estee Lauder (EL) gains from a solid focus on buyouts, travel retail network, effective launches and strong online sales.
Zacks.com featured highlights include: Ralph Lauren, Nu Skin, Tilly's, Centene and STAAR
by Zacks Equity Research
Zacks.com featured highlights include: Ralph Lauren, Nu Skin, Tilly's, Centene and STAAR
Here's Why Estee Lauder (EL) Looks Lucrative Post Q2 Earnings
by Zacks Equity Research
Estee Lauder (EL) has been gaining on buyouts, strong travel retail network and sturdy online sales. These factors drove Q2 results, which was followed by a raised outlook.
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Avon (AVP) Stock Down on Q4 Earnings and Revenues Miss
by Zacks Equity Research
Avon (AVP) posts dismal fourth-quarter 2018 results. Further, it witnesses a decline in both its Active and Ending Representatives.
NUS vs. EL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NUS vs. EL: Which Stock Is the Better Value Option?
Nu Skin (NUS) Q4 Earnings Surpass Estimates, Decrease Y/Y
by Zacks Equity Research
Nu Skin (NUS) delivers better-than-expected fourth-quarter 2018 results, wherein the top line improves year over year on solid performances across most regional segments.
Nu Skin Enterprises (NUS) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 1.94% and 1.48%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Currency be a Drag on Nu Skin's (NUS) Q4 Earnings?
by Zacks Equity Research
Nu Skin's (NUS) Q4 results to be hurt by weak gross margin and unfavorable currency translations. Nevertheless, expanding customer base and sales leaders are likely to offer respite.
Earnings Preview: Nu Skin Enterprises (NUS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Nu Skin (NUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Nu Skin's Sales Leaders & Customers Revive Lost Sheen?
by Zacks Equity Research
Nu Skin (NUS) grapples with sluggish gross margin and adverse currency trends. Nevertheless, strength in sales leaders and customers are encouraging.
Can Growth in Sales Leaders Uplift Nu Skin Stock in 2019?
by Zacks Equity Research
Nu Skin (NUS) is reeling under soft margins and adverse impacts from currency fluctuations. However, sturdy base of sales leaders and customers is likely to enhance performance.
Why Is Nu Skin (NUS) Up 1.5% Since Last Earnings Report?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moving Average Crossover Alert: Nu Skin Enterprises (NUS)
by Zacks Equity Research
Nu Skin Enterprises (NUS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Nu Skin (NUS) Stock Down on Q3 Earnings Miss, Sales Rise Y/Y
by Zacks Equity Research
Negative currency translation weighs on Nu Skin's (NUS) Q3 performance. Nevertheless, sales leaders and customer count continues to rise.
Nu Skin Enterprises (NUS) Misses Q3 Earnings Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of -2.08% and 1.75%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Sales Leaders & Customers to Aid Nu Skin's (NUS) Q3 Earnings
by Zacks Equity Research
Nu Skin's (NUS) Q3 performance to gain from a sturdy base of sales leaders and customers. Projections for the impending quarter unveil a favorable picture.
Factors Likely to Influence Meredith's (MDP) Q1 Earnings
by Zacks Equity Research
While strategic buyouts and restructuring actions serve as key growth drivers for Meredith (MDP), soft EBITDA margins may be a deterrent.
Will Monster Beverage (MNST) Beat Earnings Estimates in Q3?
by Zacks Equity Research
Monster Beverage (MNST) benefits from product innovation strategy and regular product launches. Latest additions to the Monster brand are likely to generate incremental sales and boost profitability.
Can Keurig Dr Pepper (KDP) Deliver Earnings Beat in Q3?
by Zacks Equity Research
Keurig Dr Pepper (KDP) is poised to gain from DPS' distribution strategy and innovation alongside Keurig's coffee brands and online presence. But, soft CSD trends and higher aluminum prices are woes.
Is Archer Daniels (ADM) Poised for Earnings Beat in Q3?
by Zacks Equity Research
Archer Daniels (ADM) saw a stellar start to 2018, having beaten earnings and sales in the first two quarters of 2018. Do strategies position it for a Q3 beat?